CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500820 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Kohei Tsuji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiyoda-ku, Japan. Hauptthemen laut MEDLINE: HIV-1, CD4 Antigens, Antibodies, Neutralizing, Anti-HIV Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science London, Japan Agency for Medical Research and Development, Support Program for Starting up Innovation Hub.
Abstract (Originalsprache)
Antibody‐drug conjugates (ADCs) that equip multiple cytotoxic drugs on an antibody have been developed, particularly in cancer chemotherapy. In the treatment of viral infectious diseases, there are dominantly fewer examples of ADCs. Recently, we developed double‐warhead ADCs targeting the entry of human immunodeficiency virus type 1 (HIV‐1) into host cells. One is a small molecule CD4 mimic, which is a competitive inhibitor against the interaction between a viral envelop protein, gp120, and a primary receptor, CD4, and the other is neutralizing antibodies, which recognize the regions of gp120, exposed by its conformational change after the interaction between gp120 and CD4. The conformational changes are also triggered by the binding of gp120 and a CD4 mimic, and therefore, the ADCs show positive effects on anti‐HIV‐1 activity compared to the combinational use of CD4 mimics with neutralizing antibodies. Herein, we synthesized novel ADCs containing a CD4 mimic and a neutralizing antibody, KD‐247, using tCAP chemistry, which is based on a site‐specific modification method for IgG antibodies, and evaluated their anti‐HIV‐1 and antibody‐dependent cellular cytotoxicity (ADCC) activities. As a result, the KD‐247‐adopted ADCs demonstrated enhanced anti‐HIV‐1 activities, whereas all of the ADCs reduced their ADCC activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Biomaterials and Bioengineering, Institute of Integrated Research, Institute of Science Tokyo, Chiyoda-ku, Japan.
- The Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
- Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
- Peptide Institute, Inc., Ibaraki, Japan.
- Institute for Protein Research, Osaka University, Suita, Japan.
ORCID-Profile: Hirokazu Tamamura
Förderung
- Japan Society for the Promotion of Science London
- Japan Agency for Medical Research and Development
- Support Program for Starting up Innovation Hub
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Tsuji, K., Miura, Y., Kuwata, T., Matsuzaki, R., Kobayakawa, T., Matsumoto, K., Ito, Y., Yoshiya, T., Matsushita, S., & Tamamura, H. (2026). CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202500820
Vancouver
Tsuji K, Miura Y, Kuwata T, Matsuzaki R, Kobayakawa T, Matsumoto K, et al. CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors. ChemMedChem. 2026. doi:10.1002/cmdc.202500820
BibTeX
@article{Tsuji2026,
author = {Tsuji, Kohei and Miura, Yutaro and Kuwata, Takeo and Matsuzaki, Riku and Kobayakawa, Takuya and Matsumoto, Kaho and Ito, Yuji and Yoshiya, Taku and Matsushita, Shuzo and Tamamura, Hirokazu},
title = {CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500820}
}
EUVIMED